July 24, 2017 / 12:56 PM / 2 years ago

BRIEF-Delmar Pharmaceuticals HGRAC approves application to initiate phase 2 of VAL-083

July 24 (Reuters) - Delmar Pharmaceuticals Inc

* Delmar Pharmaceuticals receives approval from China’s Human Genetic Resources Administration to initiate phase 2 clinical trial in newly diagnosed GBM

* Delmar Pharmaceuticals Inc - trial is expected to open for enrollment in coming weeks at Sun Yat-Sen University Cancer Center (SYUCC) in Guangzhou

* Delmar Pharmaceuticals Inc - HGRAC approved application to initiate phase 2 safety and efficacy study of its lead product candidate VAL-083 Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below